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Objective: To create an ideal temporary skin substitute. Methods: Temporary skin
substitute (Biobrane, AWBAT and AWBAT Plus) porosity, 3D matrix, and biochemical
composition were evaluated for impact on healing wounds (pain, ﬂuid accumulation,
infection, and time to heal). Twenty-four Sprague-Dawley [H1a: (SD) CVF] rats were
used to measure the histology of healed full-thickness wounds. Tissue culture methods
wereusedtomeasuretheinﬂuenceofImmuno-10onhumandermalﬁbroblasts:prolifer-
ation,collagen,andalpha-smoothmuscleactin.Results:Infull-thicknesswounds(rats),
histologicalevidencesuggestsbetterreepithelializationofwoundscoveredwithAWBAT
Plus than those with AWBAT. Tissue culture techniques revealed that key biological ad-
ditives to AWBAT Plus stimulated human dermal ﬁbroblast growth, collagen synthesis,
and alpha-smooth muscle actin production. Human keratinocyte growth was also pro-
moted by a key biological element in AWBAT Plus. Interestingly, human mesenchymal
stem cells grew well on the AWBAT Plus membrane. Clinically, AWBAT Plus protected
widelymeshedautograft,whichhealedmoreuniformlyandfasterthancadaverallograft.
Conclusion: AWBAT Plus shows a great promise as a major advancement in wound
care.
The search continues for a safe and cost-effective ideal temporary skin substitute that
functionsaswellas,orbetterthan,thegoldstandard(cadaverallograft).Minimalfunctional
requirementsareasfollows:(a)protectexciseddeepwoundsurfacesuntilautograftingtakes
place, resulting in equal or greater autograft and equal or fewer complications (infection or
dressing changes due to rejection, nonadherence, etc); (b) protect excised wounds covered
with widely meshed autograft until the interstices heal; and (c) limit conversion of mid-
dermal burns to full-thickness wounds
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Table 1. Types of AWBAT Plus and intended use
AWBAT Plus (6 biologicals) Intended Use
S Partial-thickness burn
D Donor site
M Widely meshed autograf
Gloves Hand burns
Novel and meaningful terminology1 was proposed for wound-dressing products re-
ferred to asbioengineeredskin,tissue-engineeredskin,andbioengineeredskinequivalents.
“Bioengineered Alternative Tissue” applies to products like Biobrane, Integra, TransCyte,
Alloderm,Apligraft,Orcell,Oasis,Epicel,GammaGraft,Laserskin, AWBAT,andAWBAT
Plus. Composition may include biologicals, such as collagen (various types and forms),
chondroitin4and/or6sulfate,vitaminCorE,growthfactorsandcytokines,andlivingcells.
AWBAT Plus was cleared by the Food and Drug Administration (FDA) in January 2010
and declared to be a “Combination Product” wound dressing device containing properties
of both a drug and a device.
Desirable properties of an ideal temporary skin substitute or bioengineered alterna-
tive tissue2,3 include adherence, moisture permeability control, safety, pain management,
ﬂexibility, transparency, stability, cost-effectiveness, and ease of application and removal.
Greenwood et al4 have shown Biobrane to possess these properties. The desirable prop-
erties are expanded for AWBAT Plus: stimulate ﬁbroblast proliferation, increase collagen
synthesis,providebetterdrapability,andcanbepreformedintoanatomicallyshapedgloves,
which enable efﬁcient and precise ﬁt to the hand wound surface, reducing time for wound
closure and anesthesia.
Six biological components are added to the 3D matrix of AWBAT Plus to increase its
hydrophilic and hygroscopic properties enabling a moist, but not wet environment, to heal
more rapidly. Vitamin C and E are natural antioxidants. Hypoallergenic type I collagen
peptide and chondroitin 4 and 6 sulfate contribute hydrophilic properties.3 Immuno-10 is
a puriﬁed carbohydrate fraction of Aloe vera, which increases the hydrophilic and hygro-
scopic nature of the 3D matrix. Different porosities (5.5% or 7.5%) accommodate wounds
with varying exudative characteristics.
AWBAT product conﬁgurations are described later. The distinction between AWBAT
and AWBAT Plus is that the former contains collagen peptide as the sole biological compo-
nent, same as Biobrane; AWBAT Plus contains 6 biological components. The S, D, and M
conﬁgurations distinguish the level of porosity and adherence needed for the type of wound
managed.
METHODS AND RESULTS
Preliminary evaluation of AWBAT-D on donor sites and AWBAT-S on superﬁcial burns5
showed that donor sites treated with AWBAT-D healed on average in 11.2 days. Pain rating
after 24 hours was 1.2. Average number of days to healing of superﬁcial burns treated
with AWBAT-S was 8.1. Pain rating after 24 hours was 1.5. There was no infection and no
hematoma/seroma.
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Table 2. Summary of Epidermal Healing
AWBAT-S Plus (Test Article)
(N = 12 animals)
AWBAT-S (Control Article)
(N = 12 animals) Grade of
Reepithelialization∗ None Minimal Partial Most Complete None Minimal Partial Most Complete
Incidence 0 0 5 4 3 0 2 3 7 0
Sood et al6 compared AWBAT-D with Acticoat and BGC Matrix. In 13 donor sites,
therewasnoﬂuidaccumulationunderAWBAT-Dandnoinfections.Therewere4infections
with Acticoat and 7 infections with BGC Matrix (19 wounds each). Average healing time
(days) was: AWBAT-D 10.8, BGC Matrix 12.4, Acticoat 14.4.
REEPITHELIALIZATION OF FULL-THICKNESS WOUNDS IN RATS
A study7 was conducted to evaluate systemic toxicity and wound healing of the AWBAT-S
Plus wound dressing following application to full-thickness dermal wounds. Twenty-four
Sprague-Dawley [H1a: (SD) CVF] rats were randomly assigned to either a comparator
control (AWBAT wound dressing) or test article (AWBAT-S Plus) group, comprosed of
6 animals per sex per group. On day 0, animals were anesthetized and 2 cm by 2 cm
full-thickness dermal wounds were aseptically created on each side of the back (2 wounds
per animal). Both wounds were covered with either the test or the control article (one
article section per wound site). Body weights and detailed examinations for clinical signs
were conducted at randomization, and at days 8 and 15. On day 15, blood was collected
for hematology and serum chemistry analysis and the animals were euthanized. A gross
necropsy was conducted; wound sites and selected organs were collected and weighed.
Microscopic evaluation of the wound sites and selected major organs was performed by a
veterinary pathologist.
Therewerenoclinicalsigns,changesinbodyororganweight,clinicallaboratorytests,
ormicroscopicﬁndingsindicativeofsystemictoxicityto AWBAT-SPlus.Theinﬂammatory
cellular response consisted of mild-to-moderate inﬁltrates of polymorphonuclear cells,
lymphocytes, and macrophages. Rare multinucleated giant cells and mineralized tissue
debris were also present, and there was no evidence of necrosis. Crusts composed of
degenerating inﬂammatory cells and keratin were frequently present on the wound surface.
Granulation tissue formation and ﬁbrosis in the dermis were generally minimal to mild.
Reepithelialization of the wound sites occurred in the control and test animals (Figs 1-4),
but tended to be more complete in the test animals of both sexes (Table 2). For the control
and test articles, males tended to have more complete reepithelialization than did the
females.
INFLUENCE OF IMMUNO-10 ON HUMAN DERMAL FIBROBLASTS:
PROLIFERATION, COLLAGEN, AND ALPHA-SMOOTH MUSCLE ACTIN
Fibroblasts are a key structural cell in skin and are crucial for wound repair. Studies were
performed to test whether or not Immuno-10, a key component of AWBAT Plus, possessed
beneﬁcial properties in terms of stimulating ﬁbroblast proliferation.8 Our initial studies
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looked at whether various amounts of Immuno-10 had any obvious deleterious effects on
the human dermal ﬁbroblasts. Fibroblasts were cultured in 96 well plates with Immuno-10
(1 mg/mL) for up to 7 days. No signs of cell toxicity such as rounding or loss of adherence
were observed. Next, the 3H-thymidine assay was used to evaluate ﬁbroblast proliferation
(see Fig 5). 3H-thymidine is taken up into newly synthesized DNA in proliferating cells.
Cells were cultured in low serum (0.1%) to render them moderately quiescent. Addition of
Immuno-10 at 1.0 or 0.1 mg/mL stimulated cell proliferation at least as well as the positive
controls (10% serum or transforming growth factor beta [TGFβ]).
Immuno-10 was also tested for ability to stimulate collagen production.9,10 Dermal
ﬁbroblasts were cultured for 48 hours with Immuno-10 (0.1 mg/mL) and collagen produc-
tion was detected using immunoﬂuorescence (see Fig 6). Transforming growth factor beta,
a known potent inducer of collagen synthesis, was used as a positive control. Interestingly,
Immuno-10 did stimulate collagen synthesis although not as strongly as TGFβ. This ability
of Immuno-10 to increase collagen could be beneﬁcial and could result in faster wound
healing. Another aspect of wound healing involves the synthesis of alpha-smooth muscle
actin (α-SMA) by ﬁbroblasts that convert to contractile cells called myoﬁbroblasts. These
cells are important for wound contraction. We detected α-SMA in ﬁbroblasts treated with
the positive control cytokine TGFβ and also when the cells were exposed to Immuno-10
(albeit less strongly than TGFβ). Fibroblasts that ramp up their production of collagen and
α-SMA may result in faster wound healing.
Figure 1. Most of the wound surface is reepithelialized and healing of the
underlying dermis is nearly complete. Small foci of mineralized debris are
present in the dermis. A small crust containing inﬂammatory cells is adhered
to the epithelium at the edge of the unhealed wound surface (H & E stain,
40× magniﬁcation).
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Figure 2. Granulation tissue with interspersed inﬂammatory cells is present
in the superﬁcial dermis underneath the wound surface, and neovasculariza-
tion is prominent (H & E stain, 200× magniﬁcation).
Figure 3. The wound surface is partially reepithelialized, and healing of the
underlying dermis is nearly complete. Small foci of mineralized debris are
present in the dermis, and a large crust containing inﬂammatory cells covers
the unhealed wound surface (artifactual space present) (H & E stain, 40×
magniﬁcation).
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Figure 4. Granulation tissue with prominent neovascularization and
interspersed inﬂammatory cells is present in the superﬁcial dermis
underneath the wound surface and adjacent epithelium. Many degen-
erating inﬂammatory cells are present in the cellular crust (H & E
stain, 200× magniﬁcation).
Figure 5. Immuno-10 stimulates human dermal ﬁbroblast pro-
liferation. Human dermal ﬁbroblasts were maintained in com-
plete DMEM 10% FBS or starved for 48 hrs in DMEM 0.1%
FBS. Starved cultures were stimulated with TGFβ (5 ng/mL) or
Immuno-10(I-10)(1.0or0.1mg/mL)for72hoursarecompared
tononstimulatedcontrol.Tritiatedthymidinelabelingforallcul-
tures was during the ﬁnal 24 hours. Statistics were evaluated
using the Student t test. DMEM indicates Dulbecco’s Modiﬁed
Eagle Medium; FBS, fetal bovine serum.
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Figure 6. Immuno-10stimulatesﬁbroblastcollagenandα-SMApro-
duction. Human dermal ﬁbroblasts were maintained in complete
DMEM 10% FBS or starved for 48 hours in DMEM 0.5% FBS.
Starved cultures stimulated with TGFβ (0.5 ng/mL) or Immuno-10
(I-10)(0.1mg/mL)for48hours.Cellswereﬁxedandlabeledwithﬂu-
orescent antibodies for collagen I and α-SMA. Cells were observed
with a digital ﬂuorescence microscope and images acquired by us-
ing the same intensity and photodetector gain to allow quantitative
comparisons of relative levels of immunoreactivity between samples.
DMEM indicates Dulbecco’s Modiﬁed Eagle Medium; FBS, fetal
bovine serum.
INFLUENCE OF IMMUNO-10 ON HUMAN KERATINOCYTE
PROLIFERATION
Human keratinocytes were also tested for their ability to be inﬂuenced by Immuno-10
in terms of their rate of proliferation by using the 3H-thymidine incorporation assay
(Fig 7). Here, the keratinocytes were cultured with a low, suboptimal amount of a spe-
cial keratinocyte growth medium (medium 154 at 0.1× concentration) with or without
Immuno-10. Interestingly, keratinocytes cultured in the suboptimal media supplemented
with Immuno-10 grew much better than those in 0.1× medium 154. In fact, the cells
proliferated as well as those grown in full strength medium 154.
HUMAN MESENCHYMAL STEM CELLS GROW ON AWBAT-S-PLUS
Human mesenchymal stem cells (MSC), derived from human cord blood, were purchased
as a viable culture (Vitro Biopharma, Golden, CO) and were maintained in low serum
mesenchymal stem cell culture medium without antibiotics or antimycotic. To test the
growth on the AWBAT-S Plus (nylon mesh side up) 5.0 × 105 MSC were plated onto the
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material in the bottom of a 24 well plate. A small amount of sterile vacuum grease was
applied to the bottom of the dish to keep the AWBAT Plus adhered to the plate bottom.
Cell growth was monitored for up to 10 days at which point the AWBAT Plus-Cell complex
was transferred, nylon mesh side up, to a glass bottom, 24 well plate and images captured
(Fig 8, panels A and B).
Figure 7. Human keratinocyte proliferation is enhanced by Immuno-
10.Humanepidermalkeratinocytesweremaintainedincomplete(1×)
medium 154 or starved for 48 hours in 0.1× medium 154. Starved
cultures stimulated with Immuno-10 (I-10) (1.0 mg/mL) for 72 hours
are compared to nonstimulated control. Tritiated thymidine labeling
for all cultures was during the ﬁnal 24 hours. Statistics were evaluated
by using the Student t test.
Figure 8. Human mesenchymal stem cells growing on AWBAT-S Plus. Panel A shows cells
growing well on the backing material and in some cases growing over the mesh (original
magniﬁcation 100×). Panel B shows a higher magniﬁcation (200×) of a different area.
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Figure 9. Sixty percent total body surface area (TBSA)
third degree postoperative day 10.
Figure 10. Sixty percent total body surface area
(TBSA) third degree postoperative day 42.
CLINICAL EXPERIENCE WITH AWBAT PLUS
AWBAT Plus has the potential to take wound coverage to the next level. It provides not
only an optimal milieu but also a stimulus to promote active wound healing. With this in
mind AWBAT-M Plus was used to cover 4:1 meshed autografts to the upper extremities of
a 26-year-old man. Because of the lack of donor sites and no ﬁnding for cultured epithelial
autografts, the lower extremities were grafted with 5:1 meshed autografts that were covered
with allograft meshed 1:1.
Two weeks later, the upper extremities were reexcised and covered with 4:1 meshed
autograft. Since AWBAT Plus was now available, it was used as a protective barrier with
factors to accelerate reepithelialization. The AWBAT Plus–treated sites were reepithelial-
ized by 14 days; yet, the allograft-covered sites on the lower extremities still had open
areas at 4 weeks. Furthermore, there was excellent adhesion of the AWBAT Plus, there
was no ﬂuid accumulation, and it was easily removed between the third and fourth weeks
postoperatively. Figures 9 and 10 show the results at 6 weeks. He continues to have a very
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satisfactory aesthetic appearance. The lower extremities have more hemosiderin deposits
within the dermis and are more heavily pigmented. In addition, there is an excellent range
of motion of the upper extremities and the grafts are very durable.
The2differenceswerethe4:1meshand5:1mesh,andAWBAT-MPlususedtoprotect
the grafts on the upper extremities and 1:1 meshed allograft on the lower extremities. A
single-case study seldom indicates a true solution, but the impressive results shown in the
photographs warrant further investigation.
DISCUSSION
Biobrane has been clinically available for 3 decades and found to be an effective tem-
porary skin substitute.2,4,12,14 El-Khatib et al11 showed that Biobrane has better long-term
adherenceonanexcisedwoundthanpigskin(EZ-Derm,GeneticLaboratories,StPaul,Min-
nesota);10daysversus3to4days.Purdueetal12 showedBiobranetobeequallyeffectiveas
frozenallograft(goldstandard)onexcisedwoundswithrespecttoautografttakesandinfec-
tion. Barret et al13 showed Biobrane to be superior to 1% silver sulfadiazine with respect to
reduction of (a) pain and pain medications, (b) wound healing time, and (c) length of hospi-
tal stay. Whitaker et al14 have shown Biobrane to be effective for a variety of clean wounds.
Hansbrough15 showeddodecylamineresponsibleforhypersensitivityreactionstoBiobrane.
Frequent ﬂuid accumulation4 beneath Biobrane on donor sites presents an opportunity
toimprovetheperformancebymakingthemembranemoreporousandfreeofcross-linking
agents (cyanuric chloride, dodecylamine). Methods were developed for making AWBAT
withauniform3Dnylonmatrixphysicallybondedtoaprecisionporoussiliconemembrane
coated with hypoallergenic type I porcine collagen peptide.
Aloe vera has been used for centuries for burn wound care. Maenthaisong et al16
showed that Aloe vera–treated burn wounds resulted in signiﬁcantly faster burn wound
healing. A puriﬁed fraction of Aloe vera (Immuno-10) is a key component of AWBAT
Plus and is shown herein to stimulate the proliferation of human skin ﬁbroblasts and
keratinocytes. In addition, stimulation of human ﬁbroblast production of collagen and
smooth muscle actin may all be desirable properties for healing of burned skin. Of interest
is the ﬁnding shown here that human mesenchymal stem cells grow well on AWBAT Plus.
This ﬁnding shows that in the future, stem cells themselves or stem cells differentiated to
different kinds of skin cells could readily be used with AWBAT Plus or be already attached
to AWBAT Plus to serve as a living “skin” replacement.
CONCLUSION
AWBAT and AWBAT Plus represent a new generation of Temporary Skin Substitutes
intended to better satisfy the desired attributes of an ideal temporary skin substitute.17-22
AWBAT was cleared by the FDA (February 2009) for use on superﬁcial wounds, donor
sites, and meshed autograft and was initially evaluated on a total of 69 wounds. Low pain
was noted when used to protect superﬁcial burns and donors sites. Importantly, there was
no ﬂuid accumulation and no infection.
AWBAT Plus was cleared by the FDA in January 2010 as a “Combination Product
Medical Device.” Immuno-10 has the ability to stimulate ﬁbroblast and keratinocyte
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proliferation and ﬁbroblast collagen synthesis. Human mesenchymal stem cells grow well
on AWBAT Plus. Reepithelialization of rat dermal wounds tended to be more complete in
animals treated with AWBAT-S Plus than in those treated with AWBAT-S.
Preliminary observation shows AWBAT Plus functions well in humans to protect
widely meshed autograft.
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